Cipla – Roche Deal – Cipla will promote and distribute Roche’s tocilizumab and Syndyma in India
Cipla Ltd and Roche Pharma India has entered an agreement under which Cipla will promote and distribute tocilizumab and Syndyma, the 2nd... Read More
Case Study: Cipla Health’s Nicotex Nicotine patches launch in Indian Market
Cipla Health, an arm Cipla with a focus on consumer healthcare products, launched Nicotex Nicotine patches. Nicotex Nicotine patch is a skin/transdermal... Read More
Cipla to acquire pharmaceuticals company Anmarate Pty Ltd
Drugmaker Cipla Ltd’s South African arm has agreed to acquire pharmaceuticals company Anmarate Pty Ltd for ZAR 26.25 million ($1.8 million) in... Read More
Cipla’s Subsidiary forms a JV in Iran
Cipla Holding B.V., a wholly owned subsidiary of the company in Netherlands, Cipla Netherlands, has entered into a joint venture agreement with... Read More
Allergan’s acquisition of Chase Pharmaceuticals – Cipla divests its 16.7% stake in Chase Pharmaceuticals Corp
Allergan plc announced acquisition of Chase Pharmaceuticals Corporation, a clinical-stage biopharmaceutical company focused on the development of improved treatments for neurodegenerative disorders... Read More
Intas Pharma to acquire Teva’s UK, Ireland generics businesses
Intas Pharmaceuticals Ltd agreed to buy Actavis UK Ltd and Actavis Ireland Ltd from Israeli generic drug maker Teva Pharmaceutical Industries Ltd... Read More
Biocon launched Gilead Sciences’ Hepatitis C drug – CIMIVIR-L in India
BIopharmaceutical company Biocon on Thursday said it has launched a generic version of Gilead Sciences’ Hepatitis C drug, Harvoni, in India. The... Read More
Top 10 Generic Pharma companies by revenue 2014
Posted on28 Nov 2015
Tagsactavis, Aspen, Aurobindo, Cipla, DRL, Fresenius Kabi, Hospira, novartis, sandoz, Stada Arzneimittel, Teva, Top 10 Generic Pharma companies by revenue 2014
Comments0
Teva – $9.1 billion Novartis (Sandoz) – $8.5 billion Allergan – $6.6 billion Mylan – $6.5 billion Actavis – $4.5 billion Aspen... Read More
Cipla looking to stregthen US business by acquiring Hetero’s US business
Posted on04 Sep 2015
Comments0
US currently contributes 8 percent to Cipla’s overall revenues and looking to strengthen further in coming years. Cipla is in advance stage... Read More
Stempeutics gets process patent from Japan for Stempeucel
Posted on10 Jun 2015
Comments0
Stempeutics Research, a firm part-owned by Cipla Ltd, said that it has won a process patent from the Japan Patent Office for... Read More